Status:
ENROLLING_BY_INVITATION
Efficacy and Safety of DS8201 in Metastatic Breast Cancer's Treatment
Lead Sponsor:
The First Hospital of Jilin University
Conditions:
Breast Cancer Metastatic
Efficacy and Safety
Eligibility:
All Genders
18-100 years
Brief Summary
This study analyzes the use of DS8201 in the treatment of metastatic breast cancer in the real world by analysis, exploring whether there are differences in effectiveness and safety between real-world...
Detailed Description
In 2022, there were 19.96 million new cancer cases worldwide, of which about 2.3 million (11.6%) were new female breast cancer, making breast cancer the most common female malignant tumor. In China, 3...
Eligibility Criteria
Inclusion
- Inclusion criteria: (1) age ≥18 years old; (2) breast cancer confirmed by pathological diagnosis; (3) the presence of one or more distant metastatic lesions confirmed by pathology or imaging; (4) patients had received DS8201 treatment; (5) Complete medical records, complete blood routine and liver and kidney function test results during treatment.
- Exclusion criteria: no history of traceable or missing clinical data.
Exclusion
Key Trial Info
Start Date :
May 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 30 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06914661
Start Date
May 25 2025
End Date
October 30 2025
Last Update
July 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Hospital of Jilin University
Changchun, Jilin, China